Nyxoah (NASDAQ:NYXH) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Nyxoah (NASDAQ:NYXH) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Stifel Nicolaus lowered their price target on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, June 17th. Oppenheimer set a $4.00 price objective on shares of Nyxoah in a report on Thursday. Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a research note on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price (down from $7.00) on shares of Nyxoah in a report on Thursday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Nyxoah has a consensus rating of “Hold” and a consensus target price of $5.26.

Nyxoah Stock Performance

NYXH stock opened at $1.47 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.38 and a debt-to-equity ratio of 0.44. Nyxoah has a twelve month low of $1.26 and a twelve month high of $8.59. The company has a market cap of $56.98 million, a P/E ratio of -0.58 and a beta of 1.62. The business has a fifty day moving average of $1.66 and a 200-day moving average of $2.93.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The firm had revenue of $8.76 million during the quarter, compared to the consensus estimate of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. As a group, equities research analysts expect that Nyxoah will post -1.59 EPS for the current year.

Institutional Trading of Nyxoah

A number of large investors have recently bought and sold shares of NYXH. Raymond James Financial Inc. bought a new position in Nyxoah in the second quarter valued at approximately $70,000. Bank of America Corp DE increased its position in shares of Nyxoah by 72.4% during the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after acquiring an additional 3,303 shares in the last quarter. Shay Capital LLC bought a new stake in shares of Nyxoah during the second quarter worth $374,000. Citadel Advisors LLC acquired a new stake in shares of Nyxoah during the third quarter worth $98,000. Finally, Deutsche Bank AG raised its holdings in shares of Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after acquiring an additional 10,000 shares during the period.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.